Epoetin zeta

Drug Profile

Epoetin zeta

Alternative Names: 1-165-Erythropoietin (human clone B03XA01), glycoform zeta; Darbepoetin alfa biosimilar - Bioceuticals; Darbepoetin alfa biosimilar - Hospira; Darbepoetin alfa biosimilar - Stada; Darbepoetin biosimilar - Bioceuticals; Darbepoetin biosimilar - Hospira; Darbepoetin biosimilar - Stada; Epo-zeta; Epoetin alfa biosimilar - Bioceuticals; Epoetin alfa biosimilar - Hospira; Epoetin alfa biosimilar - Stada; Epoetin biosimilar - Bioceuticals; Epoetin biosimilar - Hospira; Epoetin biosimilar - Stada; Epoetin Hospira; Erythropoietin alfa - Bioceuticals; Erythropoietin alfa - Stada; Erythropoietin alfa biosimilar - Hospira; Retacrit; SB 309; Silapo

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator BIOCEUTICALS Arzneimittel
  • Developer Hospira; STADA Arzneimittel
  • Class Antianaemics; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anaemia

Most Recent Events

  • 24 May 2016 Vifor Pharma gains marketing rights to epoetin zeta in USA
  • 03 Sep 2015 Hospira has been acquired by Pfizer
  • 10 Jul 2015 Launched for Anaemia (In adolescents, In children, In infants, In neonates, In adults) in Croatia (IV) before July 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top